I
Ivana T. Croghan
Researcher at Mayo Clinic
Publications - 219
Citations - 9086
Ivana T. Croghan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Smoking cessation & Nicotine. The author has an hindex of 48, co-authored 194 publications receiving 8323 citations. Previous affiliations of Ivana T. Croghan include University of Rochester & Roswell Park Cancer Institute.
Papers
More filters
Journal ArticleDOI
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Richard D. Hurt,David P.L. Sachs,Elbert D. Glover,Kenneth P. Offord,J. A. Johnston,Lowell C. Dale,M. A. Khayrallah,Darrell R. Schroeder,Penny N. Glover,C. R. Sullivan,Ivana T. Croghan,P. M. Sullivan +11 more
TL;DR: A double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation, which excluded smokers with current depression, but not those with a history of major depression.
Journal ArticleDOI
Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort.
Richard D. Hurt,Kenneth P. Offord,Ivana T. Croghan,Leigh C. Gomez-Dahl,Thomas E. Kottke,Robert M. Morse,L. Joseph Melton +6 more
TL;DR: Patients previously treated for alcoholism and/or other nonnicotine drug dependence had an increased cumulative mortality that was due more to tobacco-related than to alcohol-related causes and nicotine dependence treatment is imperative in such high-risk patients.
Journal ArticleDOI
Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism.
Kara E. Hayford,Christi A. Patten,Teresa A. Rummans,Darrell R. Schroeder,Kenneth P. Offord,Ivana T. Croghan,Elbert D. Glover,David P.L. Sachs,Richard D. Hurt +8 more
TL;DR: Bupropion is efficacious for smoking cessation independently of a former history of major depression or alcoholism, and increases in depressive symptoms during an initial period of abstinence are associated with a return to smoking.
Journal ArticleDOI
High-dose nicotine patch therapy : percentage of replacement and smoking cessation
Lowell C. Dale,Richard D. Hurt,Kenneth P. Offord,George M. Lawson,Ivana T. Croghan,Darrell R. Schroeder +5 more
TL;DR: A 44-mg/d dose of nicotine patch therapy appears to be safe for use in heavy smokers and monitoring blood cotinine levels at baseline and steady state can be used for assessing the adequacy of nicotine replacement.
Journal ArticleDOI
Varying Nicotine Patch Dose and Type of Smoking Cessation Counseling
Douglas E. Jorenby,Stevens S. Smith,Michael C. Fiore,R D Hurt,Kenneth P. Offord,Ivana T. Croghan,J T Hays,Stephen F. Lewis,Timothy B. Baker +8 more
TL;DR: There does not appear to be any general, sustained benefit of initiating transdermal nicotine therapy with a 44-mg patch dose or of providing intense adjuvant smoking cessation treatment.